Compare Equinor ASA (EQNR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Gilead Sciences, Inc. — how do they compare? Equinor ASA trades at $43 (market cap $101.62B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Equinor ASA pays the higher dividend (3.63%). Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Gilead Sciences, Inc. for 111 Days on average.
| EQNR | GILD | |
|---|---|---|
Market Cap | $101.62B | $182.40B |
Volume | 4,991,782 | 4,469,821 |
Sector | Energy | Health |
52-Week High | $45.75 | $155.80 |
52-Week Low | $22.41 | $116.74 |
Typical Hold Time | 59 Days | 111 Days |
Enterprise Value | $110.31B | $205.46B |
Dividend Yield | 3.63% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $41.61, down 3.26% today, with a bearish technical signal despite strong valuation metrics including a P/E of 11.28 and EV/EBITDA of 2.35. The company has beaten earnings estimates in two of the last three quarters, with Q3 2026 results pending. Recent news highlights expansion in LNG and carbon capture projects, while cash flow trends show improving operational performance from 2025 levels.
EQNR presents a compelling value opportunity with significant upside to the $70.50 consensus price target, though near-term technical weakness and declining profit margins from 2022 peaks pose risks. The stock's 21.32% ROE and dividend payments support income investors, while LNG expansion plans provide growth catalysts. Market sentiment remains mixed with 30% buy ratings amid energy sector volatility.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
